Revenue growth remains highly inconsistent with quarterly figures stagnating around $21.1K, while gross margins fluctuated to a negative 2.7% in 2026Q1, indicating significant challenges in scaling service delivery.
| Sales/Revenue | 77.88K | 75.73K | 45.72K | 75.4K | 60.44K | 60.29K | 48.65K | 26.9K |
| Revenue Growth % | 42.63% | 65.62% | -39.36% | 24.75% | 0.25% | 23.93% | 80.88% | - |
| Cost of Goods Sold | 123.72K | 296.31K | 129.77K | 75.73K | 65.3K | 69.17K | 66.25K | 63.18K |
| COGS % of Revenue | - | 391.27% | 283.81% | 100.43% | 108.03% | 114.73% | 136.16% | 234.9% |
| Gross Profit | -45.84K | -220.58K | -84.04K | -324 | -4.85K | -8.88K | -17.59K | -36.28K |
| Gross Margin % | -58.86% | -291.27% | -183.81% | -0.43% | -8.03% | -14.73% | -36.16% | -134.9% |
| Gross Profit Growth % | - | -162.46% | -25839.2% | 93.33% | 45.36% | 49.51% | 51.51% | - |
| Operating Expenses | 8.5M | 6.83M | 5.43M | 4.88M | 5.56M | 2.94M | 4.46M | 3.98M |
| OpEx % of Revenue | - | 9021.28% | 11873.42% | 6466.05% | 9193.16% | 4883.16% | 9166.87% | 14786.11% |
| Selling, General & Admin | 7.41M | 6.03T | 4.59M | 4M | 4.49M | 2.16M | 1.41M | 2.24M |
| SG&A % of Revenue | - | 99999900% | 10028.32% | 5307.84% | 7426.25% | 3576.44% | 2893.48% | 8329.58% |
| Research & Development | 1.15M | 1.03T | 888.77K | 873.34K | 1.07M | 787.85K | 1.05M | 1.74M |
| R&D % of Revenue | - | 99999900% | 1943.76% | 1158.21% | 1766.91% | 1306.72% | 2162.56% | 6456.53% |
| Other Operating Expenses | -60.91K | -7.06T | -45.11K | 0 | 0 | 0 | 2M | 0 |
| Operating Income | -8.55M | -7.05M | -5.51M | -4.88M | -5.56M | -2.95M | -4.48M | -4.01M |
| Operating Margin % | -10975.1% | -9312.55% | -12057.23% | -6466.48% | -9201.19% | -4897.89% | -9203.03% | -14921.01% |
| Operating Income Growth % | - | -27.92% | -13.07% | 12.33% | -88.33% | 34.05% | -11.57% | - |
| EBITDA | -8.31M | -6.82M | -5.32M | -4.71M | -5.42M | -2.77M | -4.28M | -3.84M |
| EBITDA Margin % | -10675.73% | -9012.26% | -11634.83% | -6250.74% | -8963.58% | -4588.75% | -8799.59% | -14258.45% |
| EBITDA Growth % | -50.44% | -28.29% | -12.87% | 13.01% | -95.83% | 35.38% | -11.63% | - |
| D&A (Non-Cash Add-back) | 233.15K | 227.41K | 193.14K | 162.67K | 143.62K | 186.39K | 196.28K | 178.21K |
| EBIT | -8.18M | -7.05M | -6.46M | -4.3M | -5.56M | -4.47M | -4.48M | -4.01M |
| Net Interest Income | 133.03K | 411.06K | -535.15K | -608.12K | -1.51M | -476.48K | -156.04K | -5K |
| Interest Income | 133.03K | 411.06K | 318 | 172 | 2.51K | 0 | 15 | 0 |
| Interest Expense | 0 | 0 | 535.47K | 608.29K | 1.51M | 476.48K | 156.06K | 5K |
| Other Income/Expense | 497.64K | -181.24K | -1.48M | -35.39K | -1.51M | -2M | -157.79K | -5.96K |
| Pretax Income | -8.05M | -7.23M | -6.99M | -4.91M | -7.07M | -4.95M | -4.64M | -4.02M |
| Pretax Margin % | -10336.12% | -9551.87% | -15293.78% | -6513.41% | -11694.45% | -8210.53% | -9527.35% | -14943.15% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -8.05M | -7.23M | -6.99M | -4.91M | -7.07M | -4.95M | -4.64M | -4.02M |
| Net Margin % | -10336.12% | -9551.87% | -15293.78% | -6513.41% | -11694.45% | -8210.53% | -9527.35% | -14943.15% |
| Net Income Growth % | -21.39% | -3.44% | -42.38% | 30.52% | -42.79% | -6.8% | -15.33% | - |
| Net Income (Continuing) | -8.05M | -7.23M | -6.99M | -4.91M | -7.07M | -4.95M | -4.64M | -4.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.78 | -13.61 | -7480.22 | -79782.00 | -177396.00 | -120035.00 | -110583.00 | -97680.00 |
| EPS Growth % | 99.78% | 99.82% | 90.62% | 55.03% | -47.79% | -8.55% | -13.21% | - |
| EPS (Basic) | - | -13.61 | -7480.22 | -79782.00 | -177396.00 | -120035.00 | -110583.00 | -97680.00 |
| Diluted Shares Outstanding | 2.13M | 532.04K | 943 | 62 | 42 | 50 | 50 | 50 |
| Basic Shares Outstanding | 2.13M | 532.04K | 943 | 62 | 42 | 50 | 50 | 50 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Capital structure and liquidity
According to reported financial statements, Aclarion's quarterly revenue remains highly volatile, fluctuating around the $20,000 mark, which suggests that the company has yet to achieve a repeatable commercial sales motion despite its long-standing presence in the medical technology sector as a diagnostic software provider.
The revenue trajectory appears erratic, with growth rates swinging significantly between quarters, reflecting a reliance on sporadic clinical site onboarding rather than a predictable recurring revenue stream. Investors should monitor whether the company can transition from this project-based model to a standardized, volume-driven diagnostic service.
Based on the provided income statement data, Aclarion's gross margins remain deeply inconsistent, oscillating between positive territory and significant negative values, such as the -2.7% reported in 2026Q1, which indicates that the direct costs of service delivery are not yet effectively decoupled from revenue generation.
The inability to maintain positive gross margins suggests that the current cost of revenue, likely driven by manual processing or infrastructure overhead, is disproportionate to the low scan volumes. This volatility implies that the company lacks the pricing power or operational efficiency required to support a sustainable software-as-a-diagnostic business model.
As indicated by the income statement, Aclarion's operating expenses, particularly SG&A, consistently dwarf total revenue, resulting in operating margins that remain deeply negative and show no clear trend toward narrowing despite the company's efforts to scale its proprietary diagnostic software suite across new clinical sites.
The persistent gap between SG&A and revenue suggests a lack of operating leverage, as the company continues to burn capital on commercial outreach without achieving a corresponding inflection in top-line growth. This structure implies that the business model remains highly dependent on external funding to cover its fixed operating costs.
Based on recent filings, Aclarion's cost structure is heavily weighted toward R&D and SG&A, which together frequently exceed $1.5 million per quarter, far outpacing the company's ability to generate revenue and highlighting the significant financial burden of maintaining regulatory compliance and clinical support for its technology.
The company's expense discipline appears secondary to the necessity of funding clinical validation and regulatory hurdles, which are essential for long-term viability but currently suppress any potential for profitability. This cost profile warrants further investigation into whether the company can reach a break-even point before exhausting its current liquidity.
As reported in financial data, the extreme negative operating margins and the reliance on dilutive financing suggest that Aclarion faces a precarious path forward, with the current burn rate potentially necessitating further capital raises that could significantly impact shareholder value in the near to medium term.
Short-sellers would likely focus on the disconnect between the company's clinical value proposition and its inability to convert that utility into meaningful, recurring revenue. The risk remains that the company may be unable to achieve the necessary scale before its cash runway is exhausted, rendering the current business model unsustainable.
Quick answers to the most common questions about buying ACON stock.
For fiscal year 2025, Aclarion, Inc. (ACON) reported total revenue of $0.1M. This represents a 181.6% increase compared to $0.0M in 2019.
Aclarion, Inc. (ACON) reported a net loss of $7.2M for the fiscal year ending 2025.
Aclarion, Inc. (ACON) reported an operating income of $-7.1M, resulting in an operating profit margin of -9312.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Aclarion, Inc. (ACON) generated $-0.2M in gross profit for the year, representing a gross profit margin of -291.3%. This demonstrates the company's core pricing power and production efficiency.